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Summary 
A model-based economic evaluation demonstrates that stepped approaches based on initial 
treatment with non-opioids are most likely to represent the most cost-effective regimens for 
sciatica. 
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Abstract 
The aim of this paper is to estimate the relative cost-effectiveness of treatment regimens for 
managing patients with sciatica. A deterministic model structure was constructed, based on 
information from the findings from a systematic review of clinical and cost-effectiveness, published 
sources of unit costs and expert opinion. The assumption was patients presenting with sciatica 
would be managed through one of three pathways (primary care, stepped approach, immediate 
referral to surgery).. Results were expressed as incremental cost per patient with symptoms 
successfully resolved. Analysis also included incremental cost per utility gained over a 12 month 
period. One-way sensitivity analyses were used to address uncertainty. The model demonstrated 
that none of the strategies resulted in 100% success. For initial treatments, the most successful 
regime in the first pathway was non-opioids, with a probability of success of 0.613.  In the second 
pathway, the most successful strategy was non-opioids, followed by biological agents, followed by 
epidural/nerve block and disc surgery, with a probability of success of 0.996. Pathway 3 (immediate 
surgery) was not cost-effective. Sensitivity analyses identified that the use of the highest cost 
estimates results in a similar overall picture. While the estimates of cost per QALY are higher, the 
economic model demonstrated that stepped approaches based on initial treatment with non-opioids 
are likely to represent the most cost-effective regimens for the treatment of sciatica. However, 
development of alternative economic modelling approaches is required.  
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Introduction  
 
Understanding the clinical and cost-effectiveness of different management strategies for sciatica is 
important in order to prevent patients with acute or sub-acute symptoms developing a more chronic 
condition that is resistant to treatment and likely to incur high healthcare, socio-economic costs and 
impact on patient outcomes.  It is well accepted that taking into account value for money is 
important in health care decision making.  This requires formal assessments of best available 
evidence on cost-effectiveness, and where necessary, undertaking economic modelling studies if 
there is a lack of good quality evidence. 
 
 Within the United Kingdom (UK), the prevalence of sciatica has been reported as 3.1% in men and 
1.3% in women [1 ], accounting for less than 5% of lower back pain cases presenting in primary care 
[2].  A large population study based in Finland found a lifetime prevalence of 5.3% in men and 3.7% 
in women [3]. Some cohort studies have reported that most patients will have a resolution of their 
sciatica over a period of weeks to months, with 30% having persistent, troublesome symptoms at 
one year with 20% out of work and 5-15% requiring surgery [4,5]. However, another cohort study 
found that 55% still had symptoms of sciatica two years later, and 53% after four years (which 
included 25% who had recovered after two years but had relapsed by four years) [6]. As the sciatica 
becomes chronic (>12 weeks), or with recurrent episodes, it becomes less responsive to treatment 
[7]. The cost of sciatica to society in the Netherlands in 1991 was estimated at United States (US) $ 
128 million for hospital care, US$730 million for absenteeism and US$ 708 for disablement [8]. 
According to 2013 prices, these would be US$219,490,000 (£136,524,000 US$, 125,178,000 
(£778,614,000) and US$ 1,214,056,000 (£755,149,000) respectively..  
 
There is no agreed clinical definition for sciatica, and it is commonly considered a symptom rather 
than a disease. It is characterised as being distinguishable from non-specific low back pain by specific 
clinical features. These include a unilateral well-localised leg pain, with a sharp, shooting or burning 
quality, that approximates to the dermatomal distribution of the sciatic nerve down the posterior 
lateral aspect of the leg, and usually radiates to the foot or ankle. It is often associated with 
numbness or paraesthesia in the same distribution [9,10].  
 
A variety of surgical and non-surgical treatments have been used to treat sciatica, with systematic 
reviews finding evidence for the clinical effectiveness of invasive treatments such as epidural steroid 
injection, chemonucleolysis and lumbar discectomy in the treatment of sciatica, but found 
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insufficient evidence for less invasive treatments such as bed rest and analgesia. No indirect 
comparisons across separate trials were made or examination of cost-effectiveness [11].  
 
Based on the findings of a systematic review of both clinical and cost-effectiveness [11], the aim of 
this paper is to estimate the relative cost-effectiveness of different treatment regimens for 
managing patients with sciatica. A further aim is to inform future economic modelling approaches to 
assess the relative cost-effectiveness of treatment regimes for sciatica. 
 
Methods 
 
Secondary research methods were used to undertake a model-based economic evaluation.   The first 
stage utilised the results of a systematic review to synthesise estimates of clinical effects.  The 
second stage involved the construction of the model, followed by evaluation of the base-case and 
testing the robustness of the base case findings to changes in assumptions in the data through 
sensitivity analyses. 
 
Systematic review    
 
A systematic review was undertaken according to the methodology reported in the Centre for 
Reviews and Dissemination (CRD) report [12] and the Cochrane handbook for systematic reviews of 
interventions [13].  Studies examining clinical effectiveness and those evaluating cost-effectiveness 
were reviewed separately.  
Major electronic databases (e.g. MEDLINE) and several internet sites including trial registries (e.g. 
Cochrane Central Register of Controlled Trials (CENTRAL)were searched from inception up to 
December 2009. Any comparative study or full economic evaluation was considered for inclusion. 
Studies involving adults who had sciatica or lumbar nerve root pain diagnosed clinically or confirmed 
by imaging were eligible; with a requirement for leg pain to be worse than back pain. To ensure 
consistency, this population also formed the basis for the economic model.  Studies that included 
participants with lower back pain were included only if the findings for patients with sciatica were 
reported separately. Any intervention or comparator used to treat sciatica was included. Data were 
extracted by one reviewer and checked by a second reviewer. Quality assessment was conducted 
independently by two reviewers. Disagreements  [8 papers were queried  for the health economics 
review] were resolved by discussion and, when necessary, a third reviewer was consulted. 
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For the review of clinical effectiveness, interventions were grouped into 18 treatment categories 
(see table 1). Pair-wise (standard) meta-analyses were initially conducted followed by mixed 
treatment comparison (MTC) analysis.  Analysis considered three main outcomes: global effect 
(including absence of pain), reduction in pain intensity (measured using a continuous scale) and 
improvement in function based on a composite condition-specific outcome measure (CSOM) as 
continuous data using weighted mean difference and standardised mean difference, respectively.  
 
Missing study-level outcome data, where feasible, were dealt with by inputting replacement values 
from published data such as standard deviations  standard methods, such as standard deviations 
(SDs) derived from standard errors (SEs) [13]. Where mean values were unavailable but medians 
were reported, these were used instead. If SDs for baseline values were available, these were 
substituted for missing SDs. For studies that did not report sufficient data to derive the SDs, they 
were imputed using the weighted mean [14], which was calculated separately for each intervention 
category. For the pair-wise analysis, the data were analysed according to three follow-up intervals: 
shoƌt ;≤ 6 ǁeeksͿ, ŵediuŵ ;> 6 ǁeeks to 6 ŵoŶthsͿ aŶd loŶg teƌŵ ;> 6 ŵoŶthsͿ.  
 
MTC meta-analyses were carried out to enable the simultaneous comparison of all treatment 
modalities for sciatica at a single follow-up interval (closest to 6 months). The analyses were 
conducted for the three main outcome domains, for all study designs and then after excluding 
observational studies and non-randomised trials. Prior to performing the MTC checks were 
undertaken as to  whether or not the included studies formed a closed network using level 2 
treatment categorisations with  insufficient data to use individual (level 3) treatments as nodes. This 
meant that level 2 categorisations were used in the economic model. A full report of the MTC 
methods are reported elsewhere [11].   
 
Table 1: Treatment categorisation used in the MTC analysis. 
 
Studies evaluating mixed treatments (or combination therapy) were excluded, because of the 
uncertainty regarding the extent of interaction between the combined interventions. The analyses 
were performed by the Multi-parameter Evidence Synthesis Research Group in the Bayesian 
framework [15] and the modelling computed with Markov chain Monte Carlo stimulation methods 
using Winbugs [16]. 
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The search for economic evaluations was conducted in parallel to the clinical effectiveness review. 
Given the nature and lack of homogeneity between included economic evaluations, a narrative 
review was performed on the included studies, with overall conclusions drawn. Detailed search 
methods including search protocols, search strategies and results of study selection are available as 
part of the full report of the systematic review [11]. 
 
 
The limitations of findings from the systematic review led to the development of a decision analytic 
model to estimate the relative cost-effectiveness of management strategies for patients with 
sciatica. The heterogeneous nature of the condition, the lack of recognised guidelines for the 
management of patients with sciatica and considerable variation within practice all made it 
extremely difficult to develop a model that accurately reflected current practice. The base-case 
analysis incorporated best available assumptions and data derived from the results of the systematic 
review, with sensitivity analysis undertaken to evaluate the sensitivity of the results to changes in 
important assumptions and input parameter values. The considerable level of uncertainty (seen with 
the wide variation in confidence intervals around the point estimates of global effect, as reported in 
the systematic review of clinical effectiveness [11]) restricted the development of a probabilistic 
model which could fully assess and quantify uncertainty.  
 
The decision tree, highlighted in Figure 1, was used to model patient progression through sequential 
treatment pathways with the outcome of treatment (success/failure) determining the next 
treatment event and associated health state. The cost of managing patients within each state was 
reflected in the model, although it was not envisaged that patient progression will be seamless, or 
indeed linear and uni-directional in clinical practice.  
 
The number of successful treatments was estimated over a 12-month period, together with the 
expected costs from the perspective of the UK National Health System (NHS) to determine 
interventions that would maximise health outcomes within the resource of the NHS. Out-of-pocket 
expenditures of over the counter medications (OTC), for example, were not included. This has 
important ramifications as it is assumed within the base-case model that ultimate treatment failures 
will resort to other therapies outside the conventional healthcare system, at no additional cost to 
the NHS. The influence of this assumption on modelled results was tested in sensitivity analysis. 
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A panel of 4 service providers known to the advisory group members were contacted by telephone 
to determine their usual approach to treatment in clinical practice. This information was used to 
inform which sequence of treatments to include in the economic model. Recruitment and access for 
the telephone survey was undertaken between June 2009 and September 2009. Three local health 
boards in Wales and six primary care trusts and hospital trusts in England were contacted. As 
required under the Research Governance Frameworks for England and Wales, permission was 
sought from each relevant research and development department prior to seeking and recruiting a 
range of service providers (e.g. spinal surgeons, physiotherapists, service commissioners).  
 
 The systematic review of clinical evidence [11] were used to generate a list of potential treatments 
For sciatica and guidance was consulted (e.g. MAP of Medicine).  During the telephone interviews, 
clinicians were asked initially what treatments (including combination and sequence of treatments) 
they usually use, and, afterwards, if prominent treatments identified from previous reviews were 
not mentioned, they were asked if they have ever considered using these.  
 
 
Treatment pathways 
 
A series of 100+ independent scenarios were initially considered in relation to inactive control; 
comprising any combination of initial treatment followed by intermediate treatment which may be 
followed by epidural injection and then possibly disc surgery; or immediately referred for disc 
surgery following initial treatment. This paper focuses on a subset of three treatment pathways – 
initial treatments; initial treatments followed by intermediate treatments and invasive treatments 
(epidural and disc surgery); and initial treatments followed by disc surgery. The first pathway would 
involve management within primary caƌe aŶd ƌeǀolǀe aƌouŶd ǁhat ǁas teƌŵed ͞usual Đaƌe͟, ǁith 
the use of analgesics and other medications considered , if appropriate, to attempt to secure 
symptom resolution. The treatments included within this pathway (see table 1 for further definition) 
were: 
o Usual care education/advice  
o Activity restriction 
o Non-opioids 
o Opioids 
 
The second pathway would involve a stepped approach and include the use of intermediate 
treatments (offered in addition to the initial treatments provided within primary care) – and 
provided in secondary care out-patients by multi-disciplinary teams.  The treatments included were: 
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o Manipulation 
o Traction 
o Passive physical therapy 
o Active physical therapy 
o Alternative treatments 
o Biological agents  
 
followed by more invasive treatment - epidural injections followed by disc surgery if there was no 
symptom resolution.  
 
The third pathway would involve immediate referral for surgery following initial treatment in 
primary care to alleviate symptoms.  
 
We could not identify any data to determine the proportion of patients managed through each 
pathway and therefore the treatment pathways represent the decision choices available for General 
Practionners (GPs) and their patients on presentation. Each of the pathways and the treatment 
variations availaďle ǁithiŶ theŵ ǁeƌe Đoŵpaƌed ǁith ͚iŶaĐtiǀe ĐoŶtƌol͛ ;i.e. ǁheƌe a patieŶt does 
nothing and takes into account the probability that symptoms resolve on their own accord) which, 
according to the findings from the MTC analysis, had a non-zero probability of symptom resolution. 
Indeed, counter intuitively this strategy was estimated to be more effective than usual care. In the 
base-case this reference strategy was assumed to incur no additional cost to the NHS. 
 
Figure 1: Decision tree 
 
Table 1: Treatment available within pathways 
 
The focus for the economic evaluation was on the primary outcome of global effect used in the MTC 
analysis to define probabilities of success (overall improvement or resolution) of each treatment. 
The probabilities of success for each treatment were derived from the Winbugs output from the 
MTC which are fully reported elsewhere [11]. The Winbugs output provides a summary output of the 
posterior distributions of the relevant parameters. The probability of success is the median value of 
the posterior distribution of the global effect measure. The probabilities of success are shown in 
Table 2. 
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Table 2: Probabilities of success derived from the MTC analysis 
 
Results were expressed as incremental cost per patient with symptoms successfully resolved. 
Analysis also included utility gain associated with symptom resolution, with results expressed as 
incremental cost per utility gained over a 12 month period. The heterogeneity in duration of follow 
up between studies and lack of evidence regarding relapse and recurrence rates made it difficult to 
extend the analysis beyond this time period, with the assumption made that the utility gained 
following successful treatment would continue for this period. This time period was also chosen to 
reflect the focus of the evaluation on different treatments within the period whereby treatments 
would be most effective for sciatica.  
 
 
Costs 
The costs associated with managing patients with sciatica were based on clinical opinion from 
clinical members of  the research team  and derived from published UK cost sources (2008-09 prices) 
[117,18,19] as shown in Table 3. 
 
 
 
 
Table 3: Derivation of costs 
 
Drug treatments were costed according to BNF list prices [17] at the time and calculated based on 
the dosage and durations in line with documented indications for use. Where required, it was 
assumed that dosage was based on an adult male of 65 kg. It was also assumed that paracetamol 
and ibuprofen were OTC medication; NSAIDs and Opioids would be prescribed as slow release 
tablets. Where multiple products were available, the least expensive option was applied in the base-
case.  
 
It was assumed that each prescription required a GP consultation and analgesics would be 
prescribed in accordance with the World Health Organisation (WHO)  analgesic ladder; and 
consultations would be separate. For non-opioid analgesia (NSAIDs, muscle relaxants anti-
depressants and anti-epileptic medication), two GP consultations were assumed with three 
consultations for opioid analgesia. Unit costs of GP consultations were taken from Curtis [18]. The 
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base-case analysis assumed that analgesics were prescribed separately. NSAIDs and opioids were 
costed based on single treatment for base-case analysis and multiple analgesics in the sensitivity 
analysis.  
 
Intermediate care interventions reflected treatments provided in secondary care out-patient 
settings and included non-traditional and alternative therapies. Unit costs were taken from 
published NHS Reference Costs [19]. It was assumed that an initial consultant assessment would be 
undertaken with one follow up, with routine pathology and haematology blood tests and MRI (one 
area post contrast) performed for diagnosis. Passive and physical activity therapies, manipulation 
and traction were assumed to be physiotherapy-led interventions. Biological therapies are 
unlicensed for use in sciatica in the NHS. Therefore, a similar dosage and duration in line with 
documented indications for other spinal conditions, such as ankylosing spondylitis, was assumed. For 
the base-case analysis, it was assumed that a 12 week course of Adalimumab would be prescribed 
with sub-cutaneous injection by a practice nurse. For the sensitivity analysis, it was assumed to be an 
IV administration of Infliximab in an out-patient setting with prophylactic anti-histamine.  
 
Intra-operative interventions which were included in the review of effectiveness and MTC analyses 
are extra interventions during disc surgery (e.g. introduction of steroid around exposed nerve root, 
exposed nerve root covered with a gel or membrane to reduce fibrosis)  and are not routinely 
carried out in the UK NHS and were therefore excluded. Spinal cord stimulation involves 
implantation of an electrode and is only used if disc surgery has failed and therefore was also 
excluded from the model.  
  
Epidural steroids were assumed to be a consultant out-patient intervention with one treatment 
being used in the base-case and three treatments in the sensitivity analysis.  Surgical unit costs were 
taken from NHS Reference Costs [19]. It was assumed that an initial consultant assessment would be 
undertaken with one follow up, with routine pathology and haematology blood tests and MRI (one 
area post contrast) performed for diagnosis. A follow up consultant appointment was assumed with 
one GP follow up and practice nurse intervention for removal of sutures. Surgery was costed on in-
patient extradural spinal minor  with an average length of stay of 1.9 days for base-case and in-
patient extradural spinal minor  with an average length of stay of 3.33 days, for sensitivity analysis. 
The resultant costs are shown in table 4. 
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In the base-case, ultimate failures were assumed to have no additional cost to NHS, due to patient 
reliance on OTC treatments following failure; however the extent to which this is reflected in 
practice is subject to some debate.  A sensitivity analysis related to this assumption utilised the NHS 
reference cost (mean £173; £109-205) of a consultant led face-to-face attendance for pain as an 
alternative model input, reflecting a referral of ultimate failures to a pain clinic. 
 
Table 4: Cost summary 
 
The utility values used in the model for symptoms and symptom resolution were derived from the 
literature review. However, the lack of specific utility values for sciatica symptoms pre-intervention 
and following symptom resolution was problematic. The baseline values were derived from those in 
van Hout et al. [20], using the EQ-5D, where the utility value at point of randomisation was 0.37 
(taken as utility derived from treatment failure) and the best value obtained was 0.83 (as a result of 
treatment success). These values were adjusted within the sensitivity analysis to compensate for the 
lack of consensus within the literature [11].  The subsequent effects of non-responders at each stage 
of the pathway (estimated at 5-10%) were evaluated in the sensitivity analysis. 
 
It was assumed in the base-case model that there was no reduction in utility for previous 
unsuccessful interventions, so a successful outcome was deemed to have utility 0.83 in baseline, 
regardless of how many interventions were required to achieve success. This was tested in 
sensitivity analysis.  
 
A conventional approach to examining the cost-effectiveness of the treatment regimes was 
employed. Firstly, it was determined whether any of the regimes were dominated by others, having 
both lower costs and greater probability of success and secondly, whether any of the treatments 
were subject to extended dominance, where a more expensive treatment regime strategy had a 
lower incremental cost-effectiveness ratio than the less expensive regime. This process generated 
the ͚effiĐieŶĐy fƌoŶtieƌ͛ of iŶĐƌeasiŶgly ŵoƌe Đostly aŶd ŵoƌe effeĐtiǀe ƌegiŵes foƌ the ŵaŶageŵeŶt 
of patients with sciatica.  
 
 
Sensitivity analysis 
A series of one-way sensitivity analyses were used to address uncertainty in the modelling 
assumptions and inputs. The baseline estimates utilised the best-case scenarios identified for cost 
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and then adjusted to reflect what was regarded as worst-case scenarios. Similarly, the probabilities 
of success were those determined from the WinBUGS output from the MTC in the baseline model 
and then adjusted to assess the impact on baseline findings. The utility values for symptoms and 
symptom remission were also adjusted to determine impact on baseline findings.   Additional 
sensitivity analyses adjusted for the potential of reductions in effectiveness of intermediate 
therapies and/or surgery in the stepped approach (relative reduction: 10%) and utility achieved with 
symptom resolution only as a result of successive failures (relative reduction 25%). 
 
 Results  
Whilst five full economic evaluations were identified in the systematic review [20,21,22,23, 24], the 
majority of evaluations were undertaken in conjunction with clinical trials with a lack of published 
decisions models. A full narrative review of the economic evidence has been published elsewhere 
[11]. There was considerable variation between each of the studies identified with relation to the 
management of patients with sciatica thus limiting the lessons that can be drawn from current 
evidence in order to understand the relative cost-effectiveness of current management strategies 
that reflect current practice. 
 
With regard to the provider survey, the response rate was poor from England, with only three 
contacts established. Preliminary informal interviews were conducted with four service providers. 
However, these generated wide disparities in services (e.g. whether or not an intermediate care 
service was provided) and interventions offered (e.g. biologicals were not licensed for use and so 
would not be considered), resulting in difficulty in using individual service providers to contextualise 
a geŶeƌiĐ ͚seƋueŶĐe of tƌeatŵeŶts͛ iŶ ƌelatioŶ to the fiŶdiŶgs eŵeƌgiŶg fƌoŵ the systeŵatiĐ ƌeǀieǁ 
for the purposes of developing the structure for the economic model base case.  
 
On review of these difficulties, the economic team felt that the provider survey would be better 
plaĐed oŶĐe the MTC aŶalysis ǁas Đoŵpleted iŶ oƌdeƌ to ͚ǀalidate͛ the iŶteƌǀeŶtioŶs/Đaƌe 
approaches drawn from the review findings. However, owing to time constraints, these initial 
interviews were used along with input from the steering group (clinicians on the review team) to 
build up a staged treatment approach through the assumption of patient progression through 
primary, intermediate and specialist care. 
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The clinical review showed that no therapies can deliver 100% success; the model developed here 
demonstrated that similarly none of the treatment regimens tested can provide 100% success. In 
terms of initial treatments to alleviate symptoms and wait for symptom resolution, the most 
successful regime in the first treatment pathway was non-opioids, with a probability of success of 
0.613, with 39 patients being unsuccessful for every 100 treated. When the second treatment 
pathway was considered, the most successful strategy was non-opioids, followed by biological 
agents followed by epidural/nerve block and disc surgery, with a probability of success of 0.996, that 
is 3 people out of every 1000 treated being unsuccessful.  
 
 
Table 5 highlights the mean cost, probability of success and 12-month utility gain for all possible 
treatment strategies.  
 
Table 5:  Mean cost, probability of success and utility gain 
 
The majority of treatment strategies were excluded on the grounds of strict dominance - where the 
next regime was both more effective and less costly - and by extended dominance - whereby a 
regime has an ICER that is higher than the next more effective regime. The regimes that represent 
the efficiency frontier are those based on non-opioids and are highlighted in Table 6: 
 
Table 6: Cost effectiveness acceptability efficiency frontier 
 
In terms of net benefit, four of the five strategies would be regarded as cost-effective if the ceiling 
ratio for an additional unit of utility gain over a 12-month period was <£5,100, and if the ceiling ratio 
for each additional success was <£2,500.   
 
Sensitivity Analysis 
The use of the highest cost estimates results in a similar overall picture and while the reported cost 
per quality adjusted year (QALY) estimates are higher, the stepped approaches based on non-opioids 
remain the most cost-effective strategies, as shown in Table 7.  
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Table 7:  Switching treatments using highest cost scenarios 
 
When the highest cost scenarios are employed, four of the five strategies are cost effective if the 
ceiling ratio for an additional success is <£6,000 and <£13,100 for an additional unit of utility gain.   
 
While changes to the assumptions regarding zero additional cost to the NHS following ultimate 
failure, diminishing efficacy of intermediate therapies and surgery as a result of use following failure 
of prior treatments and decreased utility gains achieved for resolution of symptoms following failure 
of prior treatments resulted in changes to the absolute results (incremental costs, benefits and 
ICERs), which regimens were identified as most cost-effective did not change. The overall 
conclusions of cost-effectiveness were thus unaffected by these sensitivity analyses. 
 
In order for the third pathway – immediate referral for surgery – to feature on the efficiency 
frontier, the costs associated with the treatment regimen following initial treatment with non-
opioids would have to fall by 49% or the likelihood of success would have to increase by 10 
percentage points to 0.95.  
 
Adjusting utility values and probability of success had limited effect on baseline findings and would 
need to be increased outside the bounds of probability to affect basic premise that stepped 
approaches are more cost-effective than direct referral for surgery following initial treatments – as 
the differential in effectiveness for disc surgery is not sufficient to offset the differential in cost from 
conducting the procedure.  
 
 
Discussion 
The economic model has demonstrated that stepped approaches based on initial treatment with 
non-opioids represent the most cost-effective regimens for the treatment of sciatica. The treatment 
regimes that comprised the efficiency frontier were inactive control; non-opioids followed by 
alternative/non-traditional treatments; non-opioids followed by alternative/non-traditional 
treatments followed by epidural; non-opioids followed by alternative/non-traditional treatments 
followed by epidural followed by disc surgery; and, non-opioids followed by biological therapies 
followed by epidural and followed by disc surgery, although this latter regime would not be regarded 
as cost-effective when measured in terms of current cost-effectiveness thresholds. Further, the 
extent of potential net benefit from these treatment strategies would have relatively minor impact 
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on NHS budgets, and when a broader societal perspective is employed the extent of such net 
benefits is likely to be considerably more. 
 
The extent to which changes in parameter estimates affect baseline findings are minor, with 
improbable reductions in cost and improvements in success rates required to suggest that direct 
referral to disc surgery represents a cost-effective approach to managing patients with sciatica. 
 
However, there are a number of limitations associated with the analysis which raise important 
points for future health economic evaluations. Firstly, the nature of the evidence has meant that the 
modelled time perspective is limited to a 12-month horizon, with no evidence available to inform 
the inclusion of relapse and recurrence within the model. The perspective of the NHS does not 
enable the consideration of issues relating to work and productivity and the preferences of patients 
for symptom resolution and treatment duration. We also acknowledge the lack of exploration from a 
personal social services perspective and that possible additional costs associated with disc surgery 
were not included. Further work is needed to establish patient preferences relating to time taken to 
achieve success and the implications of failure after a series of treatments. 
 
Secondly, the base-case assumption regarding ultimate failure having an additional zero cost to the 
NHS is contentious, but again lack of data and consensus has limited the evaluation of alternatives. It 
is highly likely that patients will resort to alternative therapies outside the conventional health care 
system. The base-case assumption that there was no reduction in utility for previous unsuccessful 
treatments is also subject to debate: assumptions had to be made on the limited information 
available; further work is needed to ensure the collection of health utility data as part of future trials 
and studies. Acknowledgement is made that the model makes the base-case assumption that when 
individual therapies are combined in sequence; effectiveness will be as high as stand-alone 
treatments.  The lack of clinical evidence precluded a full examination of the effects of successive 
treatment failures and further work is required to assess the impact of treatment sequences. 
 
Thirdly, one of the main strengths of the network meta-analysis is the wide range of treatment 
strategies used to treat sciatica that were not only considered in the same review but compared 
simultaneously in the same analysis. However, this was also its limitation. As the small number of 
relevant studies for some comparisons, statistical heterogeneity (within pair-wise comparisons) and 
potential inconsistency (between pair-wise comparisons) with the network means that the 
encouraging results for interventions such as biological agents should be interpreted with caution. 
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The findings for treatment such as surgery and epidural where more primary studies were available 
is more robust. Comparing all interventions in an economic analysis that is not based on a network 
meta-analysis means that less informal indirect analyses are made. Alternatively, the economic 
model and meta-analysis are often not conducted due to too much heterogeneity and decision 
making is based on reviewing the evidence in a  disjointed fashion. In light of the limited evidence, 
pragmatic and basic assumptions were made in order to conduct the economic evaluation. We were 
iŶteƌested iŶ the aǀeƌage tƌeatŵeŶt effeĐt of eaĐh ͚tƌeatŵeŶt appƌoaĐh͛ aŶd pooled diffeƌeŶt types 
of individual treatments (e.g. medication dosage) within each treatment approach. We therefore 
pooled clinically heterogeneous studies issuing a random-effects model, based on the assumption 
that different studies assessed different, yet related, treatment effects. However, included studies 
also varied in study design and risk of bias (methodological diversity). It was not possible to ascertain 
how much was due to clinical or methodological diversity and this needs to be taken into account in 
future work. 
 
The inclusion of anti-inflammatory biological agents within our economic model could be seen as 
contentious.  The systematic review of effectiveness considered any treatment used for sciatica in 
order to assess which is the most effective, irrespective of what is used in clinical practice in the UK.  
The economic evaluation reflected the aim of the systematic review to include all potentially 
effective treatments in the management of sciatica. The results of the systematic review 
demonstrated that although biological agents had high probability of being best and the largest 
effect estimated when compared to inactive control, these findings were associated with wide 
credible intervals, reflecting the lack of information on the estimation of effect size [25].  Sensitivity 
analysis indicated that removal of biological agents from the stepped approach made little 
difference to the cost-effectiveness results; these findings should be treated with caution. 
 
Finally, it is acknowledged that the nature of the specified model is simplistic and fails to fully 
account for structural and parameter uncertainty and distributions.  Further work is required to 
consider the implications of different modelling approaches in determining the relative cost-
effectiveness of treatment regimens relating to managing patients with sciatica; particularly to 
assess longer-term and life-time horizons of the relative cost-effectiveness of different treatments 
for sciatica and transitions between health states during the course of sciatica. However, the extent 
to which the findings from this study are likely to change would require a dramatic change in the 
evidence base surrounding the range of treatments available for use within patients. The choice of 
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the global effects as the indicator of success can also be viewed as a limitation, although it again 
would probably not have changed the nature of the findings significantly. 
 
The stepped approaches to managing sciatica based on an initial treatment with non-opioids 
represent the most cost-effective regimens relative to direct referral to disc surgery, with  positive 
net benefits emerging if the acceptable ceiling ratio for an additional unit of success was <£2,500 
with base-case costs and <£6,000 if higher costs were applied to the model.  The strategy of 
referring patients who fail initial treatments directly to disc surgery is unlikely to be cost-effective, 
with highly improbable reductions in cost and/or rates of success being required to elevate these 
regimens to the efficiency frontier.  However, these findings remain tentative and more research is 
required to develop the evidence base to inform more structurally appropriate economic models to 
inform decision making and to determine patient preferences regarding treatment durations and 
extent of invasive treatments that would be acceptable. 
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Table 1 Treatments considered within pathways  
Pathways Treatments (as defined by the level 2 categorisation 
of treatments performed in the MTC meta -analysis) 
[11] 
Initial treatments 
 Inactive control 
 Usual care 
 Education/Advice  
 Activity restriction 
 Alternative/non-traditional  (Acupunture) 
 Non-opioids 
 Opioids 
Intermediate treatments 
 Manipulation  
 Traction  
 Passive Physical Therapy   
 Active Physical Therapy  
 Biological agents 
Invasive therapies 
 Epidural/nerve Block 
 Disc surgery 
 
Table 2:  Probabilities of success derived from the MTC analysis 
Pathways Treatments 
Probability of 
success 
Probability of  
failure 
 Inactive control 0.3828 0.6172 
Initial treatments 
 Usual care 0.3393 0.6607 
 Education/Advice  0.5025 0.4975 
 Activity restriction 0.4411 0.5589 
 Non-opioids 0.6129 0.3871 
 Opioids 0.4985 0.5015 
Intermediate treatments 
 Alternative/non-traditional treatments 0.8523 0.1477 
 Biological agents 0.9074 0.0926 
 Manipulation  0.7518 0.2482 
 Traction  0.4277 0.5723 
 Passive Physical Therapy   0.4147 0.5853 
 Active Physical Therapy  0.4043 0.5957 
Invasive therapies 
 Epidural 0.6577 0.3423 
 Disc surgery 0.633 0.367 
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Table 4:  Cost summary  
Treatments Base case (£) Sensitivity analysis (£) 
Initial treatments 
Inactive control 0 0 
Usual care 73.74 80.68 
Education/Advice  81 81 
Activity restriction 70 70 
Alternative/non-traditional  70 70 
Non-opioids 122.23 129.33 
Opioids 130.26 152.71 
Biological agents 1646.74 3467.24 
Intermediate  treatments 
Manipulation  349 578 
Traction  349 578 
Passive Physical Therapy   349 578 
Active Physical Therapy  349 578 
Surgery 
Epidural 602.76 990.28 
Disc surgery  1433.66 3794.71 
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Table 3:  Derivation of costs  
Primary Care 
Description Unit Cost (£) Cost (£) Source of 
data 
GP consultation for all patients  (within 
6 weeks) 
£35  Average 2 consultations  (varies 
between 1 and 3) =£70 
Curtis 
[18] 
GP consultation for patients referred to 
intermediate care/surgery (+/- 6 weeks) 
£35 Referral usually triggered after  3 
consultation = £105 
Curtis 
[18]  
GP contact following discharge from  
intermediate care/ surgery 
£35 Typically one follow-up to GP for 
post-op analgesia/Sick note 
Curtis  
[18] 
Other primary HP contact (surgery 
patients only) 
£10 Typically one intervention to 
remove suture by practice nurse 
Curtis 
[18] 
     
Prescriptions 
Drugs Description Dose Cost (£) Continuing 
therapy 
Source of 
data 
Paracetamol  and/or 
Ibuprofen 
Likely to be 
OTC  and 
patient self 
management  
for all patients 
but GP would 
start as initial/ 
continuing  
therapy in first 
6 weeks 
Paracetamol: 
Dosage 4g per 
24 hours @ 6 
week 
prescription = 
approx 336 
tablets 
 
Ibuprofen: 
dosage 1600mg 
per 24 hours@6 
week 
prescription= 
approx=168 
tables (if 400mg 
tabs) 
 
£3.57 (based on 
16 tabs =£0.17) 
 
 
 
 
 
£3.74 (based on 
84 400mg tabs 
=£1.87) 
 
1 week cost 
 £0.60 
 
 
 
1 week cost 
 
£0.62 
BNF 59 
[19]  
Mild opioids (codeine 
phosphate) 
Prescribed if 
initial analgesia 
is not working
 
240mg per 24 
hours@6 
weeks=168tabs 
(if 60mg tablets) 
 
If added in at 
second visit  - 4 
weeks 
prescription
2 
 
6 week 
prescription= 
£11.88(28 60 
mg tabs =£1.98) 
 
 
 
4 weeks 
£7.92 
 
 
£1.98 
 
 
 
 
BNF 59 
[19]  
Other NSAIDs 
(Naproxen) 
Prescribed if 
initial analgesia 
is not working 
and/or with 
mild opioid 
1250mg per 24 
hours @ 6 
weeks = 210 
tablets 
 
4 weeks= 140 
tabs 
6 weeks = 
£10.65(based on 
250mg 28 tab) 
 
 
4 weeks=£7.10 
£1.775 BNF 59 
[19] 
Strong opioids 
(morphine) - 
considered only after 
no success with mild 
opioids/combinations 
with NSAIDs
 
Often in 
combination  
with co-
analgesic 
 
 
 £9.61 (MST 
30mg day) for 2 
weeks 
 
 
 
£4.805 
 
 
 
 
 
BNF 59 
[19] 
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Amitriptyline 
 
 
 
Or gabapentin 
 
 
 
 
 
£1.04 (25mg per 
day)  for 2 
weeks) 
 
 
£7.88 for two 
weeks (based on 
titrating dose 
from 900mg 
towards 
maximum dose) 
 
 
£0.52 
 
 
 
 
£5.52 (based 
on maximum 
dose of 3.6g as 
maintenance) 
Diazepam  For muscle 
spasm 
6mg per 24 
hours but prn 
 £1.96  BNF 59 
[19] 
      
Intermediate care 
Intervention Description Cost (£) Source of 
data 
Initial consultation First attendance consultant led 
(110N) 
£124 (94-147) - skill mix can vary 
 
NHS 
2008-9 
[20] 
 First physiotherapy contact (650A) £55 (53-53) NHS 
2008-9 
[20] 
MRI RA027- one area post contrast £195 (£142-239) NHS 
2008-9 
[20] 
Pathology Haematology 
biochemistry 
£3 (£2-4) 
£1 (1-2) 
NHS 
2008-9 
[20] 
Follow up Consultant led (110N) £86 (64-99) NHS 
2008-9 
[20] 
 Follow up physiotherapy £19 (19-19) NHS 
2008-9 
[20] 
Biological therapies Unlicensed for use in patients with 
sciatica in the NHS. Therefore, 
assumed similar dosage and 
duration in line with documented 
indications for other spinal 
conditions such as ankylosing 
spondylitis. For Adalimumab, it 
was assumed to be a 12 week 
course with sub-cutaneous 
injection by a practice nurse. For 
Infliximab (worst case), it was 
assumed to be an IV 
administration in an out-patient 
setting with prophylactic anti-
histamine.  
 
 
 
 
 
 
 
 
£1647 
 
 
£2219 
BNF 59 
[19] 
NHS 
2008-9 
[20] 
Epidural steroids Out-patient Intermediate pain 
procedure (ABO5Z) 
£190 (125-205) - up to 3  NHS 
2008-9 
[20] 
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Surgery 
Procedure Cost (£) Source of 
data 
Day case extradural spinal minor (1) without CC- HCO6c £980 (570-954) NHS 
2008-9 
[20] 
In-patient extradural spinal minor (1) without CC (HCO6c) 
Average 1.9 days stay 
£1,657 (1,956-2,314) NHS 
2008-9 
[20] 
In patient extradural spinal minor (2) without CC (HCO6c) 
Average 3.33 days stay 
£2,858 (1,699-3,184) NHS 
2008-9 
[20] 
Follow-up consultant led appointment £86 (64-99) NHS 
2008-9 
[20] 
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Table 5: Mean cost, probability of success and utility gain (1000 patients) 
 
Treatments Mean cost No. of 
successes
Inactive control 0 383
Usual care 73740 383
Usual care and active physical therapy 304324 606
Usual care and passive physical therapy   304324 613
Usual care and traction  304324 622
Usual care and manipulation  304324 836
Usual care and alternative/non-traditional treatments  304324 902
Usual care and biological agents 1161741 939
Usual care and active physical therapy and epidural 541558 865
Usual care and passive physical therapy and epidural 537416 868
Usual care and traction and epidural 532239 871
Usual care and manipulation and epidural 403168 944
Usual care and alternative/non-traditional treatments and epidural 363145 967
Usual care and biological agents and epidural 1198618 979
Usual care and active physical therapy and epidural and disc surgery 738621 951
Usual care and passive physical therapy  and epidural and disc surgery 731039 951
Usual care and traction and epidural and surgery 721562 952
Usual care and manipulation and epidural and surgery 485275 979
Usual care and alternative/non-traditional treatments and epidural and surgery 412005 988
Usual care and biological agents and epidural and surgery 1229251 992
Usual care and disc surgery 1040172 758
   
Activity restriction 70000 441
Activity restriction and active physical therapy 265056 667
Activity restriction and passive physical therapy   265056 673
Activity restriction and traction  265056 680
Activity restriction and manipulation  265056 861
Activity restriction and alternative/non-traditional treatments  265056 917
Activity restriction and biological agents 990363 948
Activity restriction and active physical therapy and epidural 465737 886
Activity restriction and passive physical therapy  and epidural 462233 888
Activity restriction and traction and epidural 457854 891
Activity restriction and manipulation and epidural 348670 953
Activity restriction and alternative/non-traditional treatments and epidural 314814 972
Activity restriction and biological agents and epidural 1021558 982
Activity restriction and active physical therapy and epidural and disc surgery 632437 958
Activity restriction and passive physical therapy  and epidural and disc surgery 626023 959
Activity restriction and traction and epidural and surgery 618006 960
Activity restriction and manipulation and epidural and surgery 418126 983
Activity restriction and alternative/non-traditional treatments and epidural and surgery 356146 990
Activity restriction and biological agents and epidural and surgery 1047471 993
Activity restriction and disc surgery 887525 795
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Opioids 130260 499
Opioids and active physical therapy 305284 701
Opioids and passive physical therapy   305284 706
Opioids and traction  305284 713
Opioids and manipulation  305284 876
Opioids and alternative/non-traditional treatments  305284 926
Opioids and biological agents 956100 954
Opioids and active physical therapy and epidural 485354 898
Opioids and passive physical therapy  and epidural 482210 900
Opioids and traction and epidural 478281 902
Opioids and manipulation and epidural 380310 957
Opioids and alternative/non-traditional treatments and epidural 349931 975
Opioids and biological agents and epidural 984092 984
Opioids and active physical therapy and epidural and disc surgery 634934 962
Opioids and passive physical therapy  and epidural and disc surgery 629179 963
Opioids and traction and epidural and surgery 621985 964
Opioids and manipulation and epidural and surgery 442633 984
Opioids and alternative/non-traditional treatments and epidural and surgery 387018 991
Opioids and biological agents and epidural and surgery 1007343 994
Opioids and disc surgery 863824 816
    
Education and advice 81000 503
Education and advice and active physical therapy 254628 704
Education and advice and passive physical therapy   254628 709
Education and advice and traction  254628 715
Education and advice and manipulation  254628 877
Education and advice and alternative/non-traditional treatments  254628 927
Education and advice and biological agents 900253 954
Education and advice and active physical therapy and epidural 433262 899
Education and advice and passive physical therapy  and epidural 430143 900
Education and advice and traction and epidural 426245 903
Education and advice and manipulation and epidural 329056 958
Education and advice and alternative/non-traditional treatments and epidural 298919 975
Education and advice and biological agents and epidural 928021 984
Education and advice and active physical therapy and epidural and disc surgery 581649 963
Education and advice and passive physical therapy  and epidural and disc surgery 575939 963
Education and advice and traction and epidural and surgery 568803 964
Education and advice and manipulation and epidural and surgery 390882 984
Education and advice and alternative/non-traditional treatments and epidural and surgery 335710 991
Education and advice and biological agents and epidural and surgery 951088 994
Education and advice and disc surgery 808713 817
   
Non-opioids 122230 613
Non-opioids and active physical therapy 257328 769
28 
 
Non-opioids and passive physical therapy   257328 773
Non-opioids and traction  257328 778
Non-opioids and manipulation  257328 904
Non-opioids and alternative/non-traditional treatments  257328 943
Non-opioids and biological agents 759683 964
Non-opioids and active physical therapy and epidural 396322 921
Non-opioids and passive physical therapy  and epidural 393895 922
Non-opioids and traction and epidural 390862 924
Non-opioids and manipulation and epidural 315240 967
Non-opioids and alternative/non-traditional treatments and epidural 291791 980
Non-opioids and biological agents and epidural 781289 988
Non-opioids and active physical therapy and epidural and disc surgery 594629 915
Non-opioids and passive physical therapy  and epidural and disc surgery 588740 917
Non-opioids and traction and epidural and surgery 581379 919
Non-opioids and manipulation and epidural and surgery 397865 965
Non-opioids and alternative/non-traditional treatments and epidural and surgery 340960 979
Non-opioids and biological agents and epidural and surgery 812116 987
Non-opioids and disc surgery 688457 858
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 1 
Table 6 Cost effectiveness acceptability efficiency frontier 2 
 3 
Treatment Cost  Prob.success Utility gain  Inc cost inc success  ICER  inc utility 
gain 
ICER 
Inactive control 0 
 
383 176 
       Non-opioids and alternative/non-traditional treatments 257328 
 
943 434 
 
257328 560 459 
 
258 999 
 Non-opioids, alternative/non-traditional treatments and 
epidural 291791 
 
980 451 
 
34463 38 916 
 
17 1992 
Non-opioids, alternative/non-traditional treatments, 
epidural and disc surgery 
320418 
 
993 457 
 
28627 12 2311 
 
6 5023 
Non-opioids, biological therapies, epidural and disc 
surgery 
799237 
 
995 458 
 
478819 3 178700 
 
 
1.23 388478 
 4 
Table 7 Cost-effectiveness efficiency frontier using highest cost scenarios 5 
 6 
Treatment Cost utility gain success Inc cost Inc success ICER inc utility ICER 
Inactive control 0 176 383      
Non-opioids  129330 282 613 129330 230 562 106 1222 
Non-opioids and alternative/non-traditional treatments  353074 434 943 223744 330 678 152 1474 
Non-opioids and alternative/non-traditional treatments and epidural 409693 451 980 56619 38 1506 17 3273 
Non-opioids and alternative/non-traditional treatments and epidural and surgery 483959 457 993 74266 12 5995 6 13032 
Non-opioids and biological agents and epidural and surgery 1553556 458 995 1069598 3 399184 1 867791 
 7 
  8 
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Figure 1: Decision-tree 1 
 2 
Decision nodes (red square): represents an event with at least two possible alternatives which are under our control. They are usually where a choice is made by a 
patient/clinician/manager relating to how a patient is diagnosed/treated/not treated 
Chance nodes (black circle): represents an event with at least two possible outcomes where the outcome is out of our control/about which there is uncertainty. For 
example, a test result can be positive/negative or a patient can respond or not respond to a treatment 
Truncated branch: the (+) indicates that the previous branches are repeated. In this diagram same success/failure options after each type of treatment 
End node (black triangle): this is a final point that terminates the branching – the end of the modelled pathway. This is where final costs or health outcomes/benefits  
are evaluated. 
